KaloCyte Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • KaloCyte's estimated annual revenue is currently $1.4M per year.(i)
  • KaloCyte's estimated revenue per employee is $77,500

Employee Data

  • KaloCyte has 18 Employees.(i)
  • KaloCyte grew their employee count by 0% last year.

KaloCyte's People

NameTitleEmail/Phone
1
President and CEO, Board DirectorReveal Email/Phone
2
VP Clinical Development/Regulatory AffairsReveal Email/Phone
3
Project DirectorReveal Email/Phone
4
Sr. Director Process DevelopmentReveal Email/Phone
5
Director OperationsReveal Email/Phone
6
Director Lab OperationsReveal Email/Phone
7
Project Manager, Agile Coach, and Regulatory Writing ConsultantReveal Email/Phone
8
Associate Scientist- Laboratory Operations ManagerReveal Email/Phone
9
Associate ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is KaloCyte?

KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $7.5M in federal awards and $2.5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, donut-shape and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$1.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M1820%N/A
#2
$2.8M18-10%N/A
#3
$1.6M186%N/A
#4
$2.8M18-10%N/A
#5
N/A18-10%N/A